

The 20th Annual



Alpha-1-Antitrypsin Laurell's Training Award

GRIFOLS

ALTA

Alpha-1-Antitrypsin Laurell's Training Award

THE ALPHA-1-ANTITRYPSIN LAURELL'S TRAINING AWARD

The primary goal of the Alpha-1-Antitrypsin Laurell's Training Award (ALTA) is to identify and engage investigators, both physicians and scientists, who are early in their careers in a longstanding commitment to investigating alpha-1-antitrypsin, its genetic background, functions and associated diseases, such as alpha-1-antitrypsin deficiency (AATD).

A total of two research grants are awarded annually: one award is dedicated to clinicians or researchers with a clinical proposal, and the second is for a basic research proposal. Both research projects are specific to the field of alpha-1-antitrypsin-related research.

The ALTA award is an international opportunity with an objective to strengthen the network between scientists and clinicians working in the field of AATD. The research grant encourages the collaboration between research institutions and clinicians, and provides an opportunity to engage with internationally recognized leading experts in the field of research on alpha-1-antitrypsin.

ABOUT THE ALTA PROGRAM

Grifols is a global biotherapeutic company committed to the discovery and development of therapies for rare, life-threatening diseases such as AATD. As a leading producer of plasma-derived medicines, Grifols is committed to identifying and supporting innovative clinical and scientific research by young investigators aimed at gaining more insight into AATD.

The ALTA Program was introduced in 2004. Since its inception, Grifols has provided more than 1.5 M Euros in research grants supporting 36 research projects in 11 countries. Over the last 18 years, ALTA-led research has elucidated the role that alpha-1-antitrypsin plays in a variety of disorders, and as a result, the scope of eligible proposals has expanded.

The ALTA award is open to research projects that generate new insights on the genetic background, pathophysiology, epidemiology, clinical course, or treatment of AATD, as well as alpha-1-antitrypsin-associated treatment options for other diseases.

The ALTA award provides:

- · Two fellowships awarded annually
- Research grant of 50,000 Euros each for a 12-month period

WHO CAN APPLY

The ALTA award is available to early career clinicians, fellows-in-training, scientists, and other Alpha-1 health care professionals under the age of 40. Individuals who are already working in the extended field of AATD as well as those new to the field are eligible to apply for the grant.

Investigators seeking to conduct all or some of their research during the ALTA fellowship at another national or international institution are especially encouraged to enter the competition.

The successful candidate will be well-trained to conduct the proposed research, an impactful project that can be materially completed in the 1-year funding window, in a favorable environment that is conducive to the proposed research, and with a strong and committed research mentorship.

This successful candidate will articulate both her /his candidacy for the award, as well as her /his vision of the impact of this award on their sustainable and long-term commitment to AATD-based research. Other favorable features of the successful application will include evidence of collaboration across centers in the proposed work, scientific relevance and impact.

REVIEW BOARD

Claus Vogelmeier (Chair)

University Hospital of Gießen and Marburg Department of Medicine Marburg, Germany

Marion Trautmann (Grifols member)

Grifols Deutschland GmbH Director of Medical Affairs EU and RoW, Frankfurt, Germany

Joanna Chorostowska-Wynimko

Laboratory of Molecular Diagnostics and Immunology National Institute of Tuberculosis and Lung Diseases Warsaw, Poland

David Lomas

Faculty of Medical Sciences University College London London, UK

James Kevin Stoller

Education Institute and Respiratory Institute Cleveland Clinic Foundation Cleveland, Ohio, USA

Noel G. McElvaney

Respiratory Research Division - Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital Dublin, Ireland

Ilaria Ferrarotti

Center for Diagnosis of Inherited Alpha1-Antitrypsin Deficiency Dept of Internal Medicine and Therapeutics Pneumology Unit IRCCS San Matteo Hospital Foundation University of Pavia Pavia, Italy

EVALUATION AND SELECTION OF RESEARCH PROPOSALS

Applications are evaluated based on merit, innovation, impact, and research environment/qualifications of the applicant.

Emphasis in the review of proposals will be placed on:

1. The candidate's personal statement of career goals and clear articulation of the impact of the award on the candidate's long-term involvement with AATD,

2. The caliber of the proposed research (i.e., impact, feasibility, and relevance), and

3. The environment in which the work is conducted (i.e., the contribution of the setting, the commitment and, the caliber of the research mentorship).

A Review Board of external experts and one Grifols expert in Alpha-1-Antitrypsin will assess and rank the grant applications.

TIMELINES FOR THE ALTA PROGRAM

Deadline for submission of letter of intent: **1 March 2023**

Deadline for submission of full proposal: **31 May 2023**

Award ceremony:

September 2023 at the European Respiratory Society (ERS) Congress

Start of funding period: September/October 2023

HOW TO APPLY

The application form and additional information can be found at: **www.alta-awards.com**




GRIFOLS SCIENTIFIC AWARDS













Award for Scientific Progress in Immunodeficiency Research



